Analyst Price Targets — OPK
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 30, 2025 8:10 pm | — | Jefferies | $1.60 | $1.46 | TheFly | Opko Health downgraded to Hold from Buy at Jefferies |
| September 17, 2024 6:52 am | Yi Chen | H.C. Wainwright | $3.00 | $1.70 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Opko Health (OPK) |
| December 15, 2022 6:56 am | — | H.C. Wainwright | $3.00 | $1.29 | Benzinga | HC Wainwright & Co. Initiates Coverage On OPKO Health with Buy Rating, Announces Price Target of $3 |
| August 4, 2022 8:38 pm | Edward Tenthoff | Piper Sandler | $4.00 | $2.40 | TheFly | Opko Health price target lowered to $4 from $5 at Piper Sandler |
Latest News for OPK
MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) OPKO Biologics, an OPKO Health company, presented preclinical data for OPK8801001 at ENDO 2026, the Endocrine Society's annual meeting. The poster, “Production and Characterization of OPK8801001, a Novel Long-Acting hGH Receptor Antagonist for the Treatment of Acromegaly,” available here, was presented by Moran Golan, Ph.D., Director of…
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock?
OPKO Health leans on RAYALDEE and key partnerships, such as BioReference and 4Kscore, as it ramps toward mid-2026 diagnostics breakeven.
Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models Data will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting WESTON, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), will announce preclinical data demonstrating the in vivo generation of…
MIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) today announced that its subsidiary EirGen Pharma Limited (EirGen) has entered into an amendment to its agreement with Nicoya Therapeutics (Macau) Limited, an affiliate of Nicoya Therapeutics (Nicoya), which grants OPKO an equity stake in Nicoya and reinforces Nicoya's commitment to commercialize RAYALDEE® in Greater China. RAYALDEE is…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OPK.
U.S. House Trading
No House trades found for OPK.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.